NCT02886715

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,110 (actual)
• Sponsor: Fougera Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 12 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	Tazarotene Cream 0.1%	Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
DRUG	Tazorac®	Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
DRUG	Placebo	Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.

Timeline

• Start date: 2016-09-21
• Primary completion: 2017-05-31
• Completion: 2017-05-31
• First posted: 2016-09-01
• Last updated: 2018-08-17
• Results posted: 2018-08-17

Locations

25 sites across 1 country: United States